View source for Prostate cancer genomes sequenced by Broad and Dana Faber

<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/21307934">http://www.ncbi.nlm.nih.gov/pubmed/21307934</a></p>
<p>&nbsp;</p>
<p><span style="font-size: medium"><br />
Nature. 2011 Feb 10;470(7333):214-20.</span></p>
<p><span style="font-size: small">The genomic complexity of primary human prostate cancer.<br />
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA.</span></p>
<p><span style="font-size: medium">The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA.</span></p>
<p><b><span style="font-size: small">Abstract<br />
</span></b><span style="font-size: small">Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.</span></p>
<p>PMID: 21307934 [PubMed - indexed for MEDLINE]</p>
<p><br />
Publication Types, MeSH Terms, Substances, Grant SupportPublication Types: <br />
Research Support, N.I.H., Extramural<br />
Research Support, Non-U.S. Gov't<br />
Research Support, U.S. Gov't, Non-P.H.S.<br />
MeSH Terms:<br />
Carrier Proteins/genetics<br />
Case-Control Studies<br />
Cell Adhesion Molecules/genetics<br />
Chromatin/genetics<br />
Chromatin/metabolism<br />
Chromosome Aberrations<br />
Chromosome Breakpoints<br />
Epigenesis, Genetic/genetics<br />
Gene Expression Regulation, Neoplastic<br />
Genome, Human/genetics*<br />
Humans<br />
Male<br />
PTEN Phosphohydrolase/genetics<br />
PTEN Phosphohydrolase/metabolism<br />
Prostatic Neoplasms/genetics*<br />
Recombination, Genetic/genetics<br />
Signal Transduction/genetics<br />
Transcription, Genetic<br />
Substances:<br />
AIP1 protein, human<br />
CADM2 protein, human<br />
Carrier Proteins<br />
Cell Adhesion Molecules<br />
Chromatin<br />
PTEN protein, human<br />
PTEN Phosphohydrolase<br />
Grant Support:<br />
2 P50 CA090381-11/CA/NCI NIH HHS/United States<br />
Howard Hughes Medical Institute/United States<br />
LinkOut - more resources</p>